Business
BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2025
BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2025.
About this update from Bioqual, Inc.
[{"type":"text","content":"\nBIOQUAL, Inc. (OTC Pink: BIOQ) www.bioqual.com:\n\n\n\n \n\n\n\nThree Months Ended\nAugust 31,\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n2024\n\n\n\n \n\n\n\n \n\n\n\n2023\n\n\n\n\n\nRevenue \n\n\n\n$\n\n\n\n11,770,482\n\n\n\n \n\n\n\n$\n\n\n\n15,578,922\n\n\n\n\n\n\n\n\n\n \n\n\n\nIncome (Loss) Before Income Tax \n\n\n\n$\n\n\n\n(931,825\n\n\n\n)\n\n\n\n$\n\n\n\n1,241,183\n\n\n\n\n\n\n\n\n\n \n\n\n\nNet Income (Loss) \n\n\n\n$\n\n\n\n(675,325\n\n\n\n)\n\n\n\n$\n\n\n\n899,483\n\n\n\n\n\n\n\n\n\n \n\n\n\nBasic Earnings per Share of Common Stock \n\n\n\n$\n\n\n\n (0.76\n\n\n\n)\n\n\n\n$\n\n\n\n1.01\n\n\n\n\n\n\n\n\n\n \n\n\n\nDiluted Earnings per Share of Common Stock \n\n\n\n $\n\n\n\n (0.76\n\n\n\n)\n\n\n\n$\n\n\n\n1.01\n\n\n\n\n\n\n\n\n\n \n\n\n\nWeighted Average\n\n\n\n\n\n\n \n\n\n\nNumber of Shares Outstanding\n\n\nFor Basic Earnings Per Share\n\n\n\n\n894,416\n\n\n\n\n\n \n\n\n894,416\n\n\n\n\n\n\n\n\n\n \n\n\n\nWeighted Average\n\n\n\n\n\n\n \n\n\n\nNumber of Shares Outstanding\n\n\nFor Diluted Earnings Per Share \n\n\n\n\n894,405\n\n\n\n\n\n \n\n\n894,406\n\n\n\n\nFor more detail related to the fiscal year 2025 unaudited first quarter results, please visit our web site at www.bioqual.com.\n\nStatements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual cost...